- Home
- LPTX vs CETY Comparison
LPTX vs CETY Comparison
Compare LPTX & CETY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- CETY
- Stock Information
- Founded
- LPTX 2011
- CETY 1993
- Country
- LPTX United States
- CETY United States
- Employees
- LPTX N/A
- CETY N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- CETY Power Generation
- Sector
- LPTX Health Care
- CETY Utilities
- Exchange
- LPTX Nasdaq
- CETY Nasdaq
- Market Cap
- LPTX 14.7M
- CETY 14.7M
- IPO Year
- LPTX N/A
- CETY N/A
- Fundamental
- Price
- LPTX $0.31
- CETY $0.24
- Analyst Decision
- LPTX Hold
- CETY
- Analyst Count
- LPTX 1
- CETY 0
- Target Price
- LPTX N/A
- CETY N/A
- AVG Volume (30 Days)
- LPTX 661.1K
- CETY 759.7K
- Earning Date
- LPTX 08-19-2025
- CETY 08-18-2025
- Dividend Yield
- LPTX N/A
- CETY N/A
- EPS Growth
- LPTX N/A
- CETY N/A
- EPS
- LPTX N/A
- CETY N/A
- Revenue
- LPTX N/A
- CETY $1,703,573.00
- Revenue This Year
- LPTX N/A
- CETY N/A
- Revenue Next Year
- LPTX N/A
- CETY N/A
- P/E Ratio
- LPTX N/A
- CETY N/A
- Revenue Growth
- LPTX N/A
- CETY N/A
- 52 Week Low
- LPTX $0.22
- CETY $0.20
- 52 Week High
- LPTX $4.79
- CETY $1.27
- Technical
- Relative Strength Index (RSI)
- LPTX 43.86
- CETY 47.88
- Support Level
- LPTX $0.30
- CETY $0.24
- Resistance Level
- LPTX $0.37
- CETY $0.30
- Average True Range (ATR)
- LPTX 0.03
- CETY 0.03
- MACD
- LPTX -0.00
- CETY 0.00
- Stochastic Oscillator
- LPTX 28.53
- CETY 35.34
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About CETY Clean Energy Technologies Inc.
Clean Energy Technologies Inc is clean energy and environmentally sustainable technologies company offering heat recovery solutions products. In addition, it also provides engineering and manufacturing solutions focused on other energy-efficient and environmentally sustainable technologies. The company's principal product is the Clean Cycle generator, offered by Heat Recovery Solutions. The company's engineering and manufacturing resources support its heat recovery solutions business. It has four segments: Clean Energy HRS & CETY Europe, CETY Renewables Waste to Energy Solutions, Engineering and Manufacturing Business and CETY HK. It serves various markets, including industrial, aerospace, military, instrumentation, and medical.